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Abstract
Purpose: In response to the COVID-19 pandemic, changes to chemotherapy services were implemented as a means of
managing imposed workload strains within health services and protecting patients from contracting COVID-19. Given
the rapidly evolving nature of the pandemic many changes were rapidly adopted and were not substantiated by robust
evidence. This study aimed to describe the changes adopted internationally to chemotherapy services, which may be
used to guide future changes to treatment delivery.
Methods: A survey was developed to understand the impact of COVID-19 on the delivery of systemic anti-cancer
therapies (SACT). It comprised 22 questions and examined the strategies implemented during the pandemic to prioritise
and protect patients receiving SACT and the participants’ professional opinion of the strategies employed. The survey
was available in English, Spanish and French and was distributed via professional bodies.
Results: 129 responses were obtained from healthcare professionals working across 17 different countries. 45% of
institutions had to implement treatment prioritisation strategies and all hospitals implemented changes in the delivery of
treatment, including: reduction in treatments (69%), using less immunosuppressive agents (50%), allowing treatment
breaks (14%) and switching to oral therapies (45%). Virtual clinic visits were perceived by participants as the most
effective strategy to protect patients.
Conclusions: The pandemic has forced chemotherapy healthcare professionals to adopt new ways of working by
reducing health interactions. Many areas of research are needed following this period, including understanding patients’
perceptions of risks to treatment, utilisation of oral treatments and the impact of treatment breaks on cancer outcomes.
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Internationally, the SARS-CoV-2 pandemic has
impacted the treatment of cancer patients.1,2
Continuity of cancer care is critical in optimising
patient outcomes; however, continuing treatments as
usual, particularly when infection prevalence remains
high, can be challenging. Reports have highlighted
that, in the course of the pandemic, there have been
reduced numbers of patients diagnosed with cancer.3
In addition, chemotherapy services in some countries
were also seeing fewer patients in the hospital setting in
order to minimise healthcare interactions to reduce the
transmission of COVID-19 infections in healthcare set-
tings.4 Changes in models of care to accommodate the
demand on healthcare systems generated by the rapid
increase in COVID-19 patients also led to the cancel-
lation of non-urgent treatments.5 Furthermore, the
requirement for social distancing in the workplace
has implications on the preparation and administration
of treatments.6
Chemotherapy is known to be immunosuppressive,
and concerns that this would result in a greater risk of
suffering from severe COVID-19 symptoms may have
caused patients and clinicians to temporarily suspend
or change cancer treatment. At the start of the pandem-
ic, decisions on the prioritisation of patients in the UK
were guided by the National Institute of Clinical
Excellence (NICE) and the main suggestion was to con-
tinue delivering therapies with curative intent.7
Anecdotal reports from different regions and coun-
tries showed that different strategies were being
adopted to delay or contain the virus. Social distancing
measures were adopted in virtually every country
affected by the disease and this meant rapidly adapting
to new ways of working. Examples of these were using
self-administration of some treatments and more oral
therapies. Understanding and sharing these measures
was important, particularly by those countries affected
early in the pandemic. In order to understand this var-
iation at a global level, we developed a survey to
explore the impact of COVID-19 on the delivery of
systemic anti-cancer treatment (SACT).
We aimed to describe the main policies or guidelines
being implemented for cancer treatment and strategies
to mitigate the impact COVID-19 has had on
cancer care.
Methods
The study used on an online questionnaire designed to
collect quantitative and qualitative data on: partici-
pants’ awareness of guidelines and policies concerning
the prioritisation and protection of cancer patients; the
strategies implemented to prioritise and protect
patients receiving systemic anti-cancer therapies; and
participants’ opinion of the effectiveness of these strat-
egies. The survey contained 22 questions and was avail-
able in English, French and Spanish (the survey
instrument can be found in Supplementary file 1).
Questionnaire development
The study questionnaire was designed to be short as it
was understood that participants would be busy at the
time of data collection. The majority of questions were
multiple-choice, and two were open-ended free-text
questions. The first free-text question asked partici-
pants to describe the changes that they perceived
were successful and unsuccessful and why. The free-
text question allowed respondents to expand on
answers in previous questions and raise concerns or
issues that had not been addressed elsewhere.
Supplementary questions enquiring about respondent
characteristics and how they were sent the survey
were also included.
Content validity
Content validity for the questionnaire was quantified
using the content validity index (CVI) as recommended
by Polit et al..8 An expert panel was assembled, which
included experts with a background in survey design,
chemotherapy treatment, and the delivery of healthcare
in the context of infectious epidemics. They were asked
to comment on three domains as recommended by
Grant & Davis:9 the relevance of each question; the
clarity of each question; and the comprehensiveness
of the entire survey. All questions were found to have
a CVI >0.78, therefore not requiring question revision
in line with the model described by Polit and col-
leagues. Revisions were made to the wording of the
questions to improve clarity and understanding based
on feedback from the expert panel. The panel unani-
mously agreed that the questionnaire was comprehen-
sive and covered the important areas. Once the
questionnaire was translated in French and Spanish,
it was again validated by two clinicians to ensure the
questions were interpreted correctly.
Sampling
The survey was open between 15th May 2020 and 9th
June 2020 and was disseminated via professional
bodies and through snowball-sampling techniques to
target healthcare professionals who had a role in deliv-
ering cancer care around the world. Professional bodies
included The British Oncology Pharmacists
Association, The International Society of Oncology
Pharmacists, The Royal College of Radiologists,
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The United Kingdom Nurses Association and The
British Urology Group.
Sample size
The population for this study were healthcare profes-
sionals involved with delivering care to cancer patients.
A sample size of 100 was calculated using the following
formula, commonly used when population mean is
unknown, where n is the sample size, Z the score for
95% confidence level, p the maximum variability of the
population at 50% and e the sampling error.
n ¼ Zð Þ2p 1 pð Þ=e2
Considering Z¼ 1.96 for 95% confidence level,
p¼ 0.5 and a sampling error of 10%, n¼ 96.125. For
rounding reasons, we believed a sample of 100 partic-
ipants was justified.
Survey administration
The study, including the questionnaire, was approved
by the University College London Research Ethics
Committee (6862/005).
The questionnaire was administered using the
Opinio Platform. Members of the societies named
above were initially contacted via an email inviting par-
ticipation. Societies that approved the survey also used
their social media platforms to disseminate the survey.
The survey introduction page acted as a consent form
and participant information sheet (Supplementary file
1). It stated that consent for data being used for
specified purposes was implied by participating in
the survey.
Missing data
We did not use ‘forced answering’ to avoid ‘missing
data’ from our online questionnaire for the open
ended questions . We allowed respondents to leave
blank questions as we believed forced answering
could result in inaccurate data. Missing data are pre-
sented within the results.
Data analysis
Data were exported from Opinio and analyses were
conducted using STATA 15. Results are presented as
count (%).
Free-text qualitative answers were compiled in a
single list and were left unedited (no corrections for
spelling or grammar). Data were analysed in Excel
using framework analysis10 to allow for the identifica-
tion of patterns across the data set. A broadly descrip-
tive type of thematic analysis was employed when
developing the themes. Codes were derived from the
data. A review of the coding of the dataset, including
the codes used, were performed by two members of the
research team to cross-check the coding and the dataset
(CM, SC). A third researcher cross-checked a percent-
age of the coding performed on the full dataset (CVP).
Themes were identified with relevant data collected
under each theme and reread to ensure the themes
appropriately captured the views and beliefs of
respondents.
Results
The questionnaire was sent to approximately 500 rele-
vant clinicians (nurses, pharmacists and doctors). In
total, 129 responses with participants from 17 countries
were obtained. Table 1 shows that the majority of par-
ticipants completed the survey in English and 46%
were from the United Kingdom.
60% participants reported some SACT had been
cancelled or postponed and reasons for these are
detailed in Table 2. In the majority of institutions,
Table 1. Overview of participants.
Parameter










Hong Kong 5 (4%)
China 4 (3%)











Clinical nurse specialist 1 (1%)





Hybrid (public & private) 7 (5%)
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the reason given for this was a revised individual
patient risk benefit balance in view of the COVID-19
pandemic; shortages of staff, equipment or resources to
shield patients from COVID-19 were cited less fre-
quently as reasons for treatments not continuing.
45% of institutions had to implement prioritisation
strategies for chemotherapy and this was mainly seen in
the United Kingdom. Not all hospitals in the United
Kingdom were prioritising treatments and some were
continuing all treatments as usual. However, all partic-
ipants reported the implementation of strategies to pro-
tect patients from unnecessary contacts. These
measures included: reduced face-to-face interactions
such as telephone clinics; the reduced frequency of
non-essential follow-ups; and the use of personal pro-
tective equipment (PPE). Table 3 describes the changes
to chemotherapy treatments that were reported in the
survey. 69% reported changes in durations of treat-
ment and 45% implemented the change of switching
therapies from intravenous to oral in an attempt to
reduce patient visits.
Participants were asked which strategies were most
effective and least effective and these were answered by
60 participants. The following themes emerged in our
analysis in relation to the effectiveness of these
strategies.
Virtual visits
Over 60 participants stated that reducing visits and
hospital footfall was effective. Virtual (telephone and
online) clinics were reported and described by one par-
ticipant as “It gives time for us to focus on a few patients
at a time and offer quality clinical service. It also shrinks
the chance of infection for both patients and caregiver to
a minimum”. Some institutions were only adopting this
for stable patients. This method of seeing patients was
not seen as ideal for all and concerns were raised about
the psychological impact to patients as described by
one doctor: “Telephone consultations can work well
for some patients, but patients still need to be seen
from time to time to accurately assess their fitness, tol-
erability of treatment and to offer patients the psycho-
logical support they have when seen by their team.’”
In addition to virtual assessments, many were using
postal deliveries to supply oral chemotherapy to patients
and had a positive experience of this service.However, one
participant referred to posting medicines as “ineffective
and reported failure of treatments to arrive on time”.
COVID-19 screening prior to hospital visits and PPE
20 participants reported both staff and patient screen-
ing was occurring at the time of this survey. Screening





Revised individual risk-benefit balance (in view of COVID-19) 74 (96%)
Lack of staff owing to redeployment to other clinical areas 4 (5%)
Lack of staff owing to staff illness or isolation 4 (5%)
Lack of bed capacity and/or equipment 5 (6%)
Insufficient resources to shield cancer patients from COVID-19 6 (8%)
Cancer care has moved to another site 2 (3%)
Other 9 (12%)
Reasons specified:
Patient choice, type of treatment, patient fearful of visiting the hospital,
hospital choice to reduce treatments and lockdown restrictions impeded patient travel
Table 3. Changes made to anti-cancer treatments.
Changes to anticancer treatments Frequency Percentage of participants (n¼ 129)
Reduced frequency or duration of treatment 89 69%
Less immunosuppressive regimens 65 50%
Increase in primary prophylaxis, e.g. antibiotics, colony stimulating factors. 65 50%
Changes in route of administration (intravenous to oral) 58 45%
Changes to treatment timing, i.e. breaks 18 14%
Other changes to anticancer therapy 18 14%
Missing values 16 12%
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of patients was carried out through phoning and ensur-
ing a patient had no COVID-19 symptoms and also
through swab testing, as described by one respondent:
“Phone screening of each patient before arrival into
clinic. We have picked up patients who needed to be
referred for COVID testing and also who had travel his-
tory which meant we needed to delay treatment.” PPE
was thought of as essential to treat patients safely and
reduce transmission.
Risk stratification/tailored treatment/prioritisation
15 respondents commented on treatment breaks and
switches to oral therapies from intravenous to keep
patients away from hospital where appropriate. In con-
trast, 10 respondents determined this as an ineffective
strategy:
“A lot of patients who have had treatment suspended due
to stable disease now (6 weeks later) seem to be showing
progression. Difficult to know if this [suspending treat-
ment] was the right thing to do.”
“Postpone the benign treatment. This will result in a long
queue and the size [of the] benign lesion is getting bigger
which [can] cause many symptoms”
Distancing in the workplace
30 respondents believed distancing in the workplace to
be ineffective, highlighting barriers such as limited
capacity for blood testing and other activities. Lack
of space in the hospital was seen as a problem in
being able to maintain safe distances. There was addi-
tional concern over patients being disallowed compan-
ions during treatment.
“Insistence of staff staying 1.5m apart, this has not been
physically possible with the number of staff we have our
small area”.
Discussion
The survey results have shown some universal strate-
gies that have been implemented and perceived as effec-
tive by clinicians from around the world, with the most
effective being the utilisation of telehealth and treat-
ment closer to home. Treatment closer to home for
cancer care has been understood to benefit many
patients and is a model of care implemented where
distances to hospital are barriers. Interestingly, despite
the model having benefits for patients and providers of
health care, it was seldom utilised prior to the pandem-
ic.11 The rapid implementation of technology and
pathways including home care have enabled patients
to both continue treatment through the
pandemicSome strategies such as switching to oral
treatments and treatment breaks are less understood.
It is not clear if these strategies will have long term
implications on a patients’ cancer. Some oral treat-
ments are equivalent to the intravenous ones, but
others are newly licensed and their place in the treat-
ment pathway is yet to be determined.12 Using routine-
ly collected national prescribing data from this period
could guide future pathway decisions for patients. Our
findings are supported by a recently published interna-
tional survey of oncology clinicians. This survey
reported a 7.7-fold increase in the proportion of con-
sultations using telehealth, however 25% of clinicians
reported concerns that increased telehealth could lead
to a worsened patient survival because of less frequent
physical assessments.13
Concerns about the psychological impact of new
models of care should also be taken into consideration.
We undertook this work in order to disseminate
strategies implemented around the world and help
others. Since our survey, international societies such
as The American Society of Clinical Oncology
(ASCO) and The European Society of Medical
Oncology (ESMO)have provided consensus guidance
in changing practice14 that are concordant with our
findings; however, our work is still valuable to share,
highlighting challenges that are faced in the health ser-
vice. Distancing in the workplace impacts on biopsies,
blood tests and chemotherapy reconstitution; all these
areas will need to be addressed in order to continue
providing a chemotherapy service which not only pro-
tects the workforce but also has the lowest impact on
patients such as increased patient waiting times. Our
work has been important in highlighting some of the
challenges faced at the beginning of the pandemic and
challenges that will continue. Although it is clear that
COVID-19 related outcomes are poor in patients with
cancer15–17 the impact of anti-cancer therapy on those
outcomes, remains contentious. The risk chemotherapy
poses on death from COVID-19 has been noted by
authors to be low. In the United States population
this was calculated as HR, 1.10; 95% CI, 0.73 to 1.60
and similarly in the United Kingdom a HR of 118
95% CI, 081–172. Models to calculate this risk
were, however, based on data collected at the time of
our survey and may not represent the whole chemo-
therapy patient population and therefore should be
used with caution.1,15
We were fortunate, despite the busy timing, to
receive 129 responses and attain the sample size
planned, reaching saturation of themes; but we would
have liked more respondents from Low- and Middle-
Income Countries (LMICs) to understand challenges
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that were faced in these settings. Furthermore, we only
gained one respondent in the US and only one chemo-
therapy nurse answered our survey. Our survey does
not put the responses into the context of case numbers
at the time of the survey, however the survey by
Chazan et al reports that 88.8% of respondents altered
cancer management or the delivery of cancer services,
with similar rates across Europa, Asia and Australia/
New Zealand, despite disparities in COVID-19 case
numbers.13
The survey was open for a short duration, only cap-
turing a snapshot of experiences and strategies imple-
mented during the pandemic. It is possible that there is
respondent bias in the sense that respondents working
in hospitals implementing strategies aimed at patient
prioritisation were more willing to take part in the
survey.
Conclusions
The pandemic has forced those working within chemo-
therapy to adopt new ways of working to reduce health
interactions. There will be many areas of research fol-
lowing this period, including understanding patients’
perceptions of risks to treatment, utilisation of oral
treatments and the impact of treatment breaks on
cancer outcomes. We believe that many models
adopted such as telehealth will continue, giving
patients’ flexibility in how they receive their care in
future, however the impact on patient outcome and
the patient perspective on these new models of care
needs to be further studied.
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